Article | August 7, 2023

Key Takeaways From The Recent FDA DCT Draft Guidance

Source: Medable

By Pamela Tenaerts, Chief Scientific Officer; Kevin Potgieter, VP Regulatory; Mohammed Ali, Chief Domain Officer

GettyImages-1257716223 fda guide

The issuance of the FDA's Decentralized Clinical Trial (DCT) Draft Guidance in May 2023 has triggered a surge of enthusiasm and expectancy in the realm of clinical trials. This highly anticipated directive marks a notable achievement in the advancement of clinical trial approaches, underscoring the FDA's endorsement of the widespread adoption of more comprehensive trial frameworks. The guidance further solidifies the FDA's dedication to fostering innovation in the design of clinical trials, while also stressing the importance of meticulous deliberation, training, supervision, and risk mitigation to ensure the effective execution of DCTs.

Get an overview of different perspectives about the draft guidance and key points that can be used to reinforce decentralized clinical trial training, oversight, and risk assessment to ensure a study's integrity, patient safety, and success.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader